Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.59 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.59 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283482 | 1.00 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL29692126 | 1.00 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL283480 | 1.00 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL28676955 | 0.98 | F7 (0.57) | F7F3SARM1SIRT2SIRT6 | |
| Niacin SCHEMBL9231503 | 0.89 | ALDH1A1 (0.70) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL834568 | 0.83 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL27764447 | 0.83 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL24170739 | 0.82 | F7 (0.57) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL5056593 | 0.79 | CYP3A4 (0.54) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL22281477 | 0.79 | CYP3A4 (0.54) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042731-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2024-08-22 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-4363415-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Tecnimede, Sociedade Técnico-Medicinal, SA (PT) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024031002-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024031002-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | CORTEVA AGRISCIENCE LLC (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-1907382-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | Portela & C.A. S.A (PT) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008028903-A2 | PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER | NEUROSEARCH A/S (DK) | 2008-03-13 | — | — | WO | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007079931-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007013830-A1 | NITROCATECHOL DERIVATIVES AS COMT INHIBITORS | PORTELA & CA. S.A. (PT) | 2007-02-01 | — | — | WO | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | SDHA, NQO1, FNTB | F7 4412/4885F3 4496/4885SARM1 1194/4885 |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | F7 2632/4885F3 587/4885SARM1 1574/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | F7 2945/4885F3 2384/4885SARM1 1635/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | F7 2632/4885F3 587/4885SARM1 1574/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | F7 2632/4885F3 587/4885SARM1 1574/4885 |
| US-20260042731-A1 | (2,4-DICHLOROPHENOXY)ACETIC ACID ANALOGS | DDT, AADAC, HACL2 | F7 2245/4885F3 4081/4885SARM1 1282/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | F7 2632/4885F3 587/4885SARM1 1574/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | F7 3688/4885F3 3316/4885SARM1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.